Core Viewpoint - The article discusses the transformative impact of AI in the medical field, particularly in enhancing decision-making processes for complex diseases like cancer, while addressing the financial uncertainties faced by patients [3][4]. Group 1: Medical AI Development - OpenEvidence, a medical AI startup, completed a Series D funding round, achieving a valuation of $12 billion, and is used by over 40% of practicing physicians in the U.S. [3] - Chinese tech giants are entering the medical AI space, with Ping An focusing on building an AI-MDT platform that integrates deep diagnosis and risk control, aiming for a more comprehensive approach than just a Q&A tool [4][5]. Group 2: Business Models in Medical AI - The medical AI landscape features two main business paths: the "dialogue path" led by internet giants, which focuses on general AI capabilities, and the "vertical tool path" represented by startups like OpenEvidence, which provide specialized information but do not address patient care directly [5][6]. - Ping An is pursuing a unique "diagnosis + payment" model, emphasizing value-based healthcare and risk management, which distinguishes it from other players in the market [6][7]. Group 3: AI-MDT Platform Features - Ping An's AI-MDT platform targets serious diseases, particularly cancer, and aims to streamline complex treatment decisions through a three-layer capability advantage: authoritative evidence-based medical foundation, deep diagnostic decision-making logic, and a commercial insurance payment and risk control system [7][8]. - The platform leverages a vast network of 50,000 collaborating physicians and real-world cancer case data to enhance AI decision-making accuracy and align it with expert opinions [8]. Group 4: Patient and Insurance Engagement - The AI-MDT service offers structured second opinions to patients, providing in-depth analysis and recommendations for treatment plans, which are verified by renowned experts [10][11]. - The integration of AI in the insurance sector aims to reduce costs while maintaining quality, creating a sustainable model that benefits both patients and insurers [11][12]. Group 5: Future Directions - Ping An plans to expand the AI-MDT service to cover more prevalent serious diseases and improve the accuracy of treatment recommendations to 90% by 2026, ensuring 100% traceability of evidence used [12].

Core Viewpoint - The article emphasizes the importance of developing a comprehensive AI-MDT (Multidisciplinary Team) platform in the healthcare sector, particularly for serious diseases like cancer, to enhance decision-making and reduce medical costs [5][9][20]. Group 1: Challenges in Cancer Treatment - Patients diagnosed with serious conditions like breast cancer face complex treatment options and significant financial uncertainty, with costs ranging from 1 million yuan for advanced therapies to 150,000 yuan for standard treatments [3][4]. - The overwhelming amount of medical information and reports creates anxiety for patients, not only regarding their health but also concerning potential financial burdens [4]. Group 2: The Role of AI in Healthcare - The global shift towards medical AI is aimed at addressing the "information decision blind spot" in healthcare, with companies like OpenEvidence leading the way in providing reliable, evidence-based information for clinical decision-making [5][7]. - Chinese tech giants are entering the medical AI space, but companies like Ping An are focusing on creating a more integrated AI-MDT platform that combines deep diagnosis with risk management, rather than just being a search tool [5][9]. Group 3: Distinct Paths in Medical AI Development - There are two main paths in the medical AI sector: the "dialogue path" led by internet giants focusing on general AI models, and the "vertical tool path" taken by startups that provide specialized medical information but do not address patient treatment directly [7][8]. - Ping An is pursuing a unique approach by integrating diagnosis and payment systems, emphasizing "value-based healthcare" and risk control, which allows for a more comprehensive solution to patient care [9][12]. Group 4: AI-MDT's Unique Advantages - Ping An's AI-MDT platform is built on a robust evidence-based medical foundation, ensuring that AI-generated recommendations are traceable and reliable [12]. - The platform leverages a vast network of over 50,000 medical experts and real-world cancer case data to enhance decision-making capabilities, aligning AI outputs with expert opinions [12][13]. Group 5: Enhancing Doctor-Patient Interaction - The AI-MDT aims to serve as a co-pilot for doctors, improving efficiency in clinical data analysis and assisting in the development of precise treatment plans [15][16]. - By empowering doctors with AI tools, the platform seeks to democratize access to high-quality medical care, ensuring that patients in both urban and rural areas receive standardized treatment [16]. Group 6: Value Creation for Patients and Insurers - The AI-MDT provides a structured second opinion service for patients, helping them navigate complex treatment options and ensuring that recommendations are validated by experts [18]. - The integration of commercial insurance into the AI-MDT framework allows for cost-effective healthcare solutions, ensuring that patients receive necessary treatments without incurring excessive costs [19]. Group 7: Future Directions - Ping An plans to expand the AI-MDT service to cover more high-incidence serious diseases and aims to improve the accuracy of treatment recommendations to 90% by 2026 [21]. - The company aspires to establish itself as a leader in the serious medical field, combining advanced technology with authoritative second opinions to create a sustainable healthcare model [21].